Your browser doesn't support javascript.
loading
An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.
Gupta, Rishi; Shipa, Muhammad; Yeoh, Su-Ann; Buck, Pauline; Ehrenstein, Michael R.
  • Gupta R; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
  • Shipa M; Department of Rheumatology, University College London, London, UK.
  • Yeoh SA; Department of Rheumatology, University College London, London, UK.
  • Buck P; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
  • Ehrenstein MR; Department of Rheumatology, University College London Hospitals NHS Trust, London, UK.
Rheumatology (Oxford) ; 60(2): 977-979, 2021 02 01.
Article en En | MEDLINE | ID: mdl-33232489
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Prioridad del Paciente / Sustitución de Medicamentos / Anticuerpos Monoclonales Humanizados / Abatacept Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Prioridad del Paciente / Sustitución de Medicamentos / Anticuerpos Monoclonales Humanizados / Abatacept Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article